Company Interview / Argenica's attracting global attention

Argenica Therapeutics (ASX: AGN) CEO Dr Liz Dallimore shares explains how the biotech's groundbreaking neuroprotective treatment, ARG-007 is progressing.

The novel Argentica Therapeutics treatment is being tested for use beyond ischemic strokes and is showing promising early results when it comes to traumatic brain injuries and strokes.

With over a decade of research and positive trials already under its belt, Dr Dallimore explains how Argenica Therapeutics continues to collaborated with global pharma partners, and remain well-funded for future trials.